These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 15577032

  • 1. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
    Ito H, Kinugasa E.
    Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Gene therapy for secondary hyperparathyroidism].
    Kanai G, Fukagawa M.
    Clin Calcium; 2010 Jul; 20(7):1052-9. PubMed ID: 20585184
    [Abstract] [Full Text] [Related]

  • 4. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors.
    Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M.
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S27-34. PubMed ID: 16109139
    [Abstract] [Full Text] [Related]

  • 5. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D, Tatematsu M.
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [Abstract] [Full Text] [Related]

  • 6. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
    Bailie GR, Massry SG, National Kidney Foundation.
    Pharmacotherapy; 2005 Dec; 25(12):1687-707. PubMed ID: 16305288
    [Abstract] [Full Text] [Related]

  • 7. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 8. [K/DOQI clinical practice guidelines for bone metabolism and disease in CKD].
    Sakaguchi T, Akizawa T.
    Clin Calcium; 2004 Sep; 14(9):9-14. PubMed ID: 15577103
    [Abstract] [Full Text] [Related]

  • 9. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM, Coyne D.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [Abstract] [Full Text] [Related]

  • 10. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
    Rodriguez M, Nemeth E, Martin D.
    Am J Physiol Renal Physiol; 2005 Feb; 288(2):F253-64. PubMed ID: 15507543
    [Abstract] [Full Text] [Related]

  • 11. [Cell proliferation of parathyroid gland in patients with progressive secondary hyperparathyroidism: Vitamin D receptor, calcium sensing receptor, and cell cycle regulation factor].
    Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M.
    Clin Calcium; 2005 Sep; 15 Suppl 1():206-16. PubMed ID: 16279026
    [No Abstract] [Full Text] [Related]

  • 12. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M, Ciceri P, Volpi EM, Olivi L, Messa PG.
    Blood Purif; 2009 Sep; 27(4):338-44. PubMed ID: 19295196
    [Abstract] [Full Text] [Related]

  • 13. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T, Yamamoto H.
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [Abstract] [Full Text] [Related]

  • 14. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
    Yano S.
    Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
    [Abstract] [Full Text] [Related]

  • 15. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism.
    González EA, Al-Aly Z, Martin KJ.
    Semin Dial; 2005 Dec; 18(3):171-4. PubMed ID: 15934956
    [Abstract] [Full Text] [Related]

  • 16. [Role of vitamin D in the pathogenesis of renal osteodystrophy].
    Nakanishi S, Fukagawa M.
    Clin Calcium; 2004 Sep; 14(9):15-20. PubMed ID: 15577104
    [Abstract] [Full Text] [Related]

  • 17. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M, Brancaccio D.
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [Abstract] [Full Text] [Related]

  • 18. [The role of calcium, calcitriol and their receptors in parathyroid regulation].
    Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB.
    Nefrologia; 2009 Apr; 29(2):103-8. PubMed ID: 19396314
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.
    J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
    [Abstract] [Full Text] [Related]

  • 20. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.
    Semin Dial; 2005 Jul; 18(3):226-38. PubMed ID: 15934970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.